Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases

NeuroToxicology

Volumn 33, Issue 5, 2012, Pages 1368-1374

  Li, Dan ^a,b   Ellis, Elizabeth M ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Aldo keto reductases; Carbonyl toxicity; Neurotoxicity; SiRNA

Indexed keywords

ALDEHYDE; ALDO KETO REDUCTASE; HYDROGEN PEROXIDE; OXIDOREDUCTASE; SMALL INTERFERING RNA; UMBELLIFERONE; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA CELL; CELL STRESS; DETOXIFICATION; ENZYME INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; NEUROPROTECTION; NEUROTOXICITY; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FAMILY; UPREGULATION;

3-HYDROXYSTEROID DEHYDROGENASES; ALDEHYDE REDUCTASE; ASTROCYTOMA; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; HYDROXYPROSTAGLANDIN DEHYDROGENASES; OXIDANTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UMBELLIFERONES; UP-REGULATION;

EID: 84867234457     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.08.015     Document Type: Article

References (48)

1. Agyeman A.S., Chaerkady R., Shaw P.G., Davidson N.E., Visvanathan K., Pandey A., et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat 2011, 132:175-180.
2. Ahmed M.M., Wang T., Luo Y., Ye S., Wu Q., Guo Z., et al. Aldo-keto reductase-7A protects liver cells and tissues from acetaminophen-induced oxidative stress and hepatotoxicity. Hepatology 2011, 54:1322-1332.
3. Barski O.A., Tipparaju S.M., Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008, 40:553-560.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-250.
5. Burcham P.C., Kerr P.G., Fontaine F. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep 2000, 5:47-50.
6. Burczynski M.E., Sridhar G.R., Palackal N.T., Penning T.M. The reactive oxygen species- and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem 2001, 276:2890-2897.
7. Chang K.C., Paek K.S., Kim H.J., Lee Y.S., Yabe-Nishimura C., Seo H.G. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 2002, 61:1184-1191.
8. Chen J., Adikari M., Pallai R., Parekh H.K., Simpkins H. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2008, 61:979-980.
9. Clark R.B., Su Y.F., Ortmann R., Cubeddu L., Johnson G.L., Perkins J.P. Factors influencing the effect of hormones on the accumulation of cyclic AMP in cultured human astrocytoma cells. Metabolism 1975, 24:343-350.
10. Corvino V., Marchese E., Zarkovic N., Zarkovic K., Cindric M., Waeg G., et al. Distribution and time-course of 4-hydroxynonenal, heat shock protein 110/105 family members and cyclooxygenase-2 expression in the hippocampus of rat during trimethyltin-induced neurodegeneration. Neurochem Res 2011, 36:1490-1500.
11. Ellis E.M. Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 2007, 115:13-20.
12. Emerit J., Edeas M., Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004, 58:39-40.
13. Gerlier D., Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 1986, 94:57-60.
14. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001, 18:685-690.
15. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 2006, 97:1634-1658.
16. Higgins L.G., Hayes J.D. Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. Drug Metab Rev 2011, 43:92-100.
17. Ireland L.S., Harrison D.J., Neal G.E., Hayes J.D. Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. Biochem J 1998, 332(Pt 1):21-30.
18. Jin Y., Penning T.M. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007, 47:263-270.
19. Kanthasamy A., Jin H., Anantharam V., Sondarva G., Rangasamy V., Rana A., et al. Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 2012, 33:833-837.
20. Kelly V.P., Ellis E.M., Manson M.M., Chanas S.A., Moffat G.J., McLeod R., et al. Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver. Cancer Res 2000, 60:957-960.
21. Kruman I., Bruce-Keller A.J., Bredesen D., Waeg G., Mattson M.P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997, 17:5089-5100.
22. Le Calve B., Rynkowski M., Le Mercier M., Bruyere C., Lonez C., Gras T., et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 2010, 12:727-730.
23. Li D., Ferrari M., Ellis E.M. Human aldo-keto reductase AKR7A2 protects against the cytotoxicity and mutagenicity of reactive aldehydes and lowers intracellular reactive oxygen species in hamster V79-4 cells. Chem Biol Interact 2012, 195:25-30.
24. Li D., Hinshelwood A., Gardner R., McGarvie G., Ellis E.M. Mouse aldo-keto reductase AKR7A5 protects V79 cells against 4-hydroxynonenal-induced apoptosis. Toxicology 2006, 226:172-180.
25. Lou H., Du S., Ji Q., Stolz A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by Nrf2. Mol Pharmacol 2006, 69:1662-1672.
26. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001, 22:187-190.
27. Lyon R.C., Johnston S.M., Watson D.G., McGarvie G., Ellis E.M. Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells: role of the aldo-keto reductase AKR7A2. J Biol Chem 2007, 282:25986-25992.
28. Lyon RC, Li D, McGarvie G, Ellis EM. Aldo-keto reductases mediate constitutive and inducible protection against aldehyde toxicity in human neuroblastoma SH-SY5Y cells, unpublished.
29. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998, 19:33-40.
30. Mattson M.P., Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 2006, 29:632-640.
31. O'Connor T., Ireland L.S., Harrison D.J., Hayes J.D. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 1999, 343(Pt 2):487-490.
32. Park A.L., Lin H.K., Yang Q., Sing C.W., Fan M., Mapstone T.B., et al. Differential expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol 2010, 3:743-750.
33. Parmar C., Kaushal M.K. Aegle marmelos. Wild fruits 1982, Kalyani Publishers, New Delhi.
34. Paya M., Halliwell B., Hoult J.R. Peroxyl radical scavenging by a series of coumarins. Free Radic Res Commun 1992, 17:293-300.
35. Picklo M.J., Olson S.J., Hayes J.D., Markesbery W.R., Montine T.J. Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Res 2001, 916:229-230.
36. Reed T.T. Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 2011, 51:1302-1319.
37. Rivett A.J., Smith I.L., Tipton K.F. The enzymes catalysing succinic semialdehyde reduction in rat brain. Biochem Pharmacol 1981, 30:741-750.
38. Schaller M., Schaffhauser M., Sans N., Wermuth B. Cloning and expression of succinic semialdehyde reductase from human brain. Eur J Biochem 1999, 265:1056-1060.
39. Schaur R.J. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med 2003, 24:149-150.
40. Shepherd A.G., Manson M.M., Ball H.W., McLellan L.I. Regulation of rat glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) subunits by chemopreventive agents and in aflatoxin B(1)-induced preneoplasia. Carcinogenesis 2000, 21:1827-1834.
41. Srivastava S., Chandra A., Bhatnagar A., Srivastava S.K., Ansari N.H. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 1995, 217:741-746.
42. Subramaniam S.R., Ellis E.M. Esculetin-induced protection of human hepatoma HepG2 cells against hydrogen peroxide is associated with the Nrf2-dependent induction of the NAD(P)H: quinone oxidoreductase 1 gene. Toxicol Appl Pharmacol 2011, 250:130-140.
43. Subramaniam SR, Ellis EM. Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's Disease, unpublished.
44. Thuong P.T., Pokharel Y.R., Lee M.Y., Kim S.K., Bae K., Su N.D., et al. Dual anti-oxidative effects of fraxetin isolated from Fraxinus rhinchophylla. Biol Pharm Bull 2009, 32:1527-1532.
45. Tobin J.E., Cui J., Wilk J.B., Latourelle J.C., Laramie J.M., McKee A.C., et al. Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Res 2007, 1139:42-50.
46. Veitch Z.W., Guo B., Hembruff S.L., Bewick A.J., Heibein A.D., Eng J., et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009, 19:477-480.
47. Webster J., Urban C., Berbaum K., Loske C., Alpar A., Gartner U., et al. The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox Res 2005, 7:95-100.
48. Wu F.J., Sheu S.J. Analysis and processing of Chinese herbal drugs: the study of Fructus aurantti immaturus. Chin Pharm J 1992, 44:257-260.